Skip to main content
Advertisement

Main menu

  • Home
  • Content
    • Current Issue
    • Publication Preview--Ahead of Print
    • Past Issue Archive
    • Case of the Week Archive
    • Classic Case Archive
    • Case of the Month Archive
    • COVID-19 Content and Resources
  • For Authors
  • About Us
    • About AJNR
    • Editors
    • American Society of Neuroradiology
  • Submit a Manuscript
  • Podcasts
    • Subscribe on iTunes
    • Subscribe on Stitcher
  • More
    • Subscribers
    • Permissions
    • Advertisers
    • Alerts
    • Feedback
  • Other Publications
    • ajnr

User menu

  • Subscribe
  • Alerts
  • Log in

Search

  • Advanced search
American Journal of Neuroradiology
American Journal of Neuroradiology

American Journal of Neuroradiology

  • Subscribe
  • Alerts
  • Log in

Advanced Search

  • Home
  • Content
    • Current Issue
    • Publication Preview--Ahead of Print
    • Past Issue Archive
    • Case of the Week Archive
    • Classic Case Archive
    • Case of the Month Archive
    • COVID-19 Content and Resources
  • For Authors
  • About Us
    • About AJNR
    • Editors
    • American Society of Neuroradiology
  • Submit a Manuscript
  • Podcasts
    • Subscribe on iTunes
    • Subscribe on Stitcher
  • More
    • Subscribers
    • Permissions
    • Advertisers
    • Alerts
    • Feedback
  • Follow AJNR on Twitter
  • Visit AJNR on Facebook
  • Follow AJNR on Instagram
  • Join AJNR on LinkedIn
  • RSS Feeds
Review ArticleADULT BRAIN
Open Access

Dentate Update: Imaging Features of Entities That Affect the Dentate Nucleus

K.M. Bond, W. Brinjikji, L.J. Eckel, D.F. Kallmes, R.J. McDonald and C.M. Carr
American Journal of Neuroradiology August 2017, 38 (8) 1467-1474; DOI: https://doi.org/10.3174/ajnr.A5138
K.M. Bond
aFrom Mayo Clinic School of Medicine (K.M.B.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for K.M. Bond
W. Brinjikji
bthe Department of Radiology (W.B., L.J.E., D.F.K., R.J.M., C.M.C.), Mayo Clinic, Rochester, Minnesota.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for W. Brinjikji
L.J. Eckel
bthe Department of Radiology (W.B., L.J.E., D.F.K., R.J.M., C.M.C.), Mayo Clinic, Rochester, Minnesota.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for L.J. Eckel
D.F. Kallmes
bthe Department of Radiology (W.B., L.J.E., D.F.K., R.J.M., C.M.C.), Mayo Clinic, Rochester, Minnesota.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for D.F. Kallmes
R.J. McDonald
bthe Department of Radiology (W.B., L.J.E., D.F.K., R.J.M., C.M.C.), Mayo Clinic, Rochester, Minnesota.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for R.J. McDonald
C.M. Carr
bthe Department of Radiology (W.B., L.J.E., D.F.K., R.J.M., C.M.C.), Mayo Clinic, Rochester, Minnesota.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for C.M. Carr
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • References
  • PDF
Loading

Abstract

SUMMARY: The dentate nucleus is a cerebellar structure involved in voluntary motor function and cognition. There are relatively few entities that affect the dentate, and the clinical features of these conditions are often complex and nonspecific. Because these entities are rarely encountered, the formulation of a differential diagnosis can be difficult. Many of the conditions are reversible or treatable with early intervention. Therefore, it is important to recognize classic clinical presentations and their associated characteristic imaging findings. We provide a summary of entities that affect the dentate nucleus and a diagnostic workflow for approaching dentate nucleus imaging abnormalities.

ABBREVIATION:

Gd3+
free gadolinium

The deep cerebellar nuclei are key structures of the cerebrocerebellar circuitry that relay output from the cerebellar cortex to supratentorial cortical and subcortical targets. The dentate nucleus is the largest of the deep cerebellar nuclei, and it is involved in planning, initiating, and modifying voluntary movements as well as cognition. Because it is buried deep within cerebellar white matter, the dentate is uncommonly lesioned as a result of trauma or surgical interventions. However, a few entities specifically involve the dentate nuclei. Many of the conditions that affect the dentate are medically manageable, and prognoses can be favorable with early intervention. Despite the fact that they are rare entities, knowing the characteristic imaging findings for these conditions will allow the formulation of an appropriate differential diagnosis of dentate nucleus abnormalities and will assist in making a timely diagnosis. In this article, we review the clinical presentations and imaging features of many of the most common entities that involve the dentate. We also provide a summary of major inherited conditions and their presentations (On-line Table) and a diagnostic approach for evaluating dentate nucleus abnormalities (Fig 1).

Fig 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig 1.

Diagnostic approach for dentate nucleus imaging abnormalities.

Normal Anatomy and Function of the Dentate

The dentate nucleus is the largest and most lateral of the 4 deep cerebellar nuclei (Fig 2). The emboliform and globose nuclei, collectively referred to as the interposed nuclei, are positioned more medially, and the fastigial nucleus lies adjacent to the midline. The dentate nucleus is located within the cerebellar white matter and is directly adjacent to the vermis and the roof of the fourth ventricle bilaterally.1,2 While the dentate is classically known to be involved in planning and executing voluntary movements, it has also been implicated in higher level cognition and sensory processing.3⇓–5 It contains anatomically separate domains that mediate these motor and nonmotor functions.6,7

Fig 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig 2.

Illustration of the location of the dentate nucleus within the cerebellum. Used with permission of Mayo Foundation for Medical Education and Research, all rights reserved.

The dentate receives ascending projections from the spinocerebellar tract via the inferior cerebellar peduncle, which convey proprioceptive information about the length and tension of muscle fibers. It also receives descending projections from the premotor and supplementary motor cortices, which are involved in planning and initiating voluntary movements.2 By integrating these 2 inputs, the dentate is able to compare intended movement with muscle feedback to maintain equilibrium and balance. Its efferent projections travel through the superior cerebellar peduncle and red nucleus to the ventrolateral thalamus, where it is involved in timing and fine-tuning voluntary movements.8

It is 1 of 3 interconnected structures collectively referred to as the myoclonic triangle or the triangle of Guillain-Mollaret. This triangular circuit comprises the red nucleus, the inferior olivary nucleus, and the dentate nucleus.9,10 Parvocellular red nucleus fibers project to the ipsilateral inferior olivary nucleus by way of the central tegmental tract. Efferents of the inferior olivary nucleus travel through the inferior cerebellar peduncle to the contralateral dentate nucleus. The dentate nucleus sends inhibitory GABAergic fibers through the superior cerebellar peduncle to the contralateral red nucleus, completing the triangular circuit.11 Together, these structures control fine voluntary movement. Disruptions in the circuit that disinhibit the inferior olivary nucleus give rise to hypertrophic olivary degeneration, which can result in the clinical syndrome of palatal tremor.9

Entities Involving the Dentate Nuclei

Hypertensive Hemorrhages.

Long-standing hypertension is associated with the formation and rupture of Charcot-Bouchard microaneurysms in small penetrating blood vessels of the cerebral circulation.12 Intracerebral hemorrhage is characterized by sudden onset of a focal neurologic deficit and may be associated with headache, altered consciousness, nausea, and vomiting. Cerebellar hypertensive hemorrhage is typically caused by rupture of the perforating arteries of the superior cerebellar artery. The most common symptoms of cerebellar hemorrhage are ataxia, vertigo, severe nausea, and vomiting. Bleeding often begins in the dentate nucleus and spreads throughout the ipsilateral hemisphere to include the cerebellar peduncles and fourth ventricle.13 There is a potential for the hemorrhage to extend through the vermis to the contralateral hemisphere.

As with all hemorrhages, CT can be used to quickly identify acute bleeding. On MR imaging, T2* sequences are key to identifying areas of prior microhemorrhage and hemosiderin deposition. These T2* hypointense microhemorrhages are characteristically concentrated in the dentate, basal ganglia, thalamus, and pons (Fig 3).14

Fig 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig 3.

Hypertensive hemorrhage. A 55-year-old man who presented with a thalamic hemorrhage. Three selected images from 3D susceptibility-weighted imaging demonstrate microhemorrhages and hemosiderin deposition within the dentate nuclei (white arrows), brain stem, thalamus, and basal ganglia. The sentinel bleed is shown with black arrows. This distribution is characteristic of hypertensive microhemorrhages. The patient was being treated with multiple medications to control his hypertension, which remained elevated even during his hospitalization.

Transient Edema from Metronidazole.

Metronidazole is an antibiotic indicated in the treatment of a variety of bacterial and protozoan infections. While it is generally a safe medication, it crosses the blood-brain barrier and can cause serious neurologic side effects at high doses and with prolonged use. Symptoms of metronidazole toxicity include ataxia, encephalopathy, peripheral neuropathy, and seizures.15 Symptoms often resolve completely following metronidazole discontinuation.

There have been reports of bilateral signal changes in the supratentorial white matter and the dentate nucleus (Fig 4) following the initiation of metronidazole therapy, both at doses within and above the recommended range.16⇓–18 These lesions are symmetric and hyperintense on T2WI and can demonstrate associated restricted diffusion. Like the symptoms associated with metronidazole toxicity, edema is reversible and imaging studies return to baseline within a few weeks of metronidazole discontinuation.18

Fig 4.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig 4.

Metronidazole toxicity. A 74-year-old woman was treated for 6 weeks with metronidazole and developed dysarthria. T2 FLAIR images demonstrate T2 hyperintensity within the dentate nuclei (A, arrows), which resolved on MR imaging 1 month later (B).

Gadolinium Deposition.

Gadolinium-based contrast agents are frequently used in imaging studies. Because free gadolinium (Gd3+) is a cytotoxic element, it must be bound to a chelator that is eliminated by renal excretion when given as a contrast agent. From a safety standpoint, it is imperative that the gadolinium-chelator bond remain stable to ensure that free gadolinium is not deposited in tissues. However, Gd3+ deposition has been found in the bones of patients and animals with normal renal function following gadolinium-based contrast exposure.19

The dentate nucleus and globus pallidus have also shown high signal intensity on unenhanced T1-weighted MR imaging following multiple contrast imaging studies.20⇓–22 The number of previous contrast administrations is positively correlated with abnormal signal intensity.20 Recently, it has been confirmed that the high T1 signal in the dentate nucleus (Fig 5) and globus pallidus is due to Gd3+ deposition.23 The mechanism by which Gd3+ deposits preferentially in the dentate is not known, and to date, there have been no studies linking Gd3+ deposition to deficits in neurocognitive function or movement disorders.24

Fig 5.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig 5.

Gadolinium deposition. A 13-year-old boy was diagnosed with a pilocytic astrocytoma and treated with chemotherapy, but no radiation. A, the first available pregadolinium T1WI without any abnormality in the dentate. B, A follow-up examination performed 10 years later now demonstrates T1 hyperintensity on TIWI within the dentate nuclei (arrows). The patient had undergone 37 gadolinium-enhanced examinations at this time point.

Multiple Sclerosis.

Multiple sclerosis is an autoimmune disease of the central nervous system that affects 90 in every 100,000 individuals in the United States, with a higher prevalence in women.25 It is characterized by a cell-mediated autoimmune response against oligodendrocyte components, leading to demyelination and axonal degeneration in the brain and spinal cord. Although MS is classically known to be a disease of white matter, substantial damage and volume loss of gray matter structures can be present.26⇓–28

Prior studies have demonstrated high intrinsic T1 signal in the dentate nuclei of patients with MS. However, patients with MS tend to undergo multiple contrast-enhanced MRIs for both diagnosis and disease surveillance. Thus, the T1-weighted hyperintensity seen in the dentate nucleus in patients with MS may be a result of their large cumulative gadolinium load rather than a manifestation of their disease. Lesions demonstrating T1 hyperintensity and T2 hypointensity in deep gray matter structures, including the dentate nucleus, thalamus, striatum, and globus pallidus, can be present as well. Such lesions have been attributed to abnormal deposition of nonheme iron and evidence of MS progression.29⇓–31 It is possible that iron deposition is a by-product of neural degeneration rather than a true marker of MS progression. However, treatment with natalizumab decreases the rate of iron deposition in patients with MS, suggesting that MS-mediated inflammatory processes contribute to the phenomenon.32,33 Future studies would be needed to determine whether gadolinium or iron deposition is responsible for signal changes in the dentate of these patients.

Iron Deposition in Neurodegenerative Conditions.

There are 10 inherited neurodegenerative diseases that are characterized by iron accumulation in the basal ganglia, substantia nigra, and deep cerebellar nuclei. These rare diseases are collectively referred to as neurodegeneration with brain iron accumulation, and their combined incidence is estimated to be <1 in 1,000,000.34 Their etiologies are heterogeneous and related to defects in iron metabolism and homeostasis, cell membrane integrity, and myelin synthesis.35 The clinical symptoms of neurodegeneration with brain iron accumulation depend on which structures are involved, but many present with extrapyramidal abnormalities and cognitive dysfunction during young adulthood.34 All neurodegeneration with brain iron accumulation subtypes are progressive, and treatment consists of symptom management because there are currently no cures for the underlying disorders.

The iron deposition is best visualized on 3D susceptibility-weighted imaging as symmetric hypointensity in the affected structures. Woodhouse-Sakati syndrome is a neurodegeneration with brain iron accumulation subtype characterized by iron deposition in the globus pallidus and dentate as well as white matter abnormalities (Fig 6).

Fig 6.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig 6.

Neurodegeneration with brain iron accumulation. A 40-year-old woman with Woodhouse-Sakati syndrome found to have neurodegenerative iron accumulation. Marked hypointensity within the dentate on T2WI (A, white arrows) and 3D SWI (B, black arrows) is consistent with iron deposition.

Fahr Disease.

Fahr disease is a rare, autosomal dominant disorder that affects <1 per 1,000,000 individuals.36 It most often presents in the fourth or fifth decade of life, with progressive extrapyramidal and neuropsychiatric symptoms such as spasticity, athetosis, dysarthria, and dementia.36 While the molecular underpinnings of Fahr disease are not well-elucidated, it has been associated with a number of endocrine disorders that affect circulating calcium levels. Treatment currently aims to alleviate symptoms and manage any coexisting hormone imbalances.

Fahr disease is characterized by idiopathic calcification of the basal ganglia and other brain regions involved in motor control, including the dentate nucleus (Fig 7) and thalamus.37⇓–39 This entity has a characteristic appearance on CT of dense, symmetric calcification most commonly in the basal ganglia, but also within the dentate nucleus, thalamus, and subcortical white matter.38 The globus pallidus is typically the first structure to be affected.36 There is no correlation between the degree of calcification and the severity of symptoms. On MR imaging, these areas of calcification can have variable T1 and T2 signal intensities that relate to the stage of disease, the degree of calcium deposition, and variance in calcium metabolism. In general, these areas will be markedly hypointense on T2*-based imaging and hypointense on T2WI and have hyperintense regions on T1WI.40 In addition, MR imaging can depict associated inflammatory changes that can later calcify and may be responsible for current symptoms.39

Fig 7.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig 7.

Fahr disease. A–D, CT and T2* gradient recalled-echo images from a 49-year-old patient with Fahr disease demonstrate dense calcification of the dentate nuclei and basal ganglia. E and F, Dense calcification within the dentate nuclei and basal ganglia is also well-demonstrated on susceptibility-weighted imaging, in this case from a 68-year-old affected woman.

Leigh Syndrome.

Leigh syndrome, or subacute necrotizing encephalomyelopathy, is a rare mitochondrial disease that affects 1 in 50,000 neonates.41 It is most commonly associated with a mutation in SURF1, a gene necessary for cytochrome C oxidase assembly and a functional mitochondrial respiratory chain.42 Early signs of the disease usually present within the first year of life, though it can have a late onset in adolescents and adults.43 Infants typically present with developmental delay or regression.43,44 Other signs may include seizures, dysphagia, ophthalmoparesis, nystagmus, dystonia, and ataxia. The prognosis is poor, and affected children are expected to live for only a few months after diagnosis.43,44 There is no cure for Leigh disease, and treatment is targeted at symptom management.

Leigh disease characteristically presents on imaging as symmetric T2 hyperintensity (Fig 8) and restricted diffusion of the dentate nuclei, basal ganglia, thalami, periaqueductal gray, substantia nigra, pons, and medulla.43,45,46 White matter is typically spared. The T2 hyperintensities and T1 hypointensities on MR imaging are reflective of vacuolation and spongiform changes.46 MR spectroscopy may demonstrate high levels of choline and lactate. Evidence of global atrophy can be seen as the disease progresses.46

Fig 8.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig 8.

Leigh disease. An 11-year-old girl diagnosed at 2 years of age with Leigh disease. Marked T2 hyperintensity on FLAIR within the dentate nuclei (A and B) and basal ganglia (C). MR spectroscopy with voxel sampling of the basal ganglia (D) demonstrates a prominent lactate doublet (at 1.3 ppm) and elevated choline (at 3.2 ppm).

Friedreich Ataxia.

Friedreich ataxia is an autosomal recessive disease that affects approximately 2 in every 100,000 people.47 It is the most common type of inherited ataxia. Clinical presentation is variable because the disease has a variety of manifestations in the central and peripheral nervous system, heart, pancreas, and skeletal muscle. Friedreich ataxia typically presents during childhood and progresses with time, though there have been reports of onset as late as 75 years of age.47 The most common presenting symptom is progressive gait ataxia. Care is targeted at managing symptoms and addressing cardiac or endocrine manifestations of the disease.

The most common primary sites of pathologic changes in patients with Friedreich ataxia are the spinal cord and peripheral nerves.48 Thus, MR imaging consistently demonstrates atrophy of the cervical spine.49 Friedreich ataxia is also associated with selective atrophy of large neurons of the dentate nucleus with sparing of small neurons.50⇓–52 It is unclear whether the high concentration of iron in the dentate nucleus makes it particularly susceptible to disease-mediated degeneration because other iron-rich structures, such as the substantia nigra, red nucleus, and globus pallidus, are spared.50 Wallerian degeneration of the superior cerebellar peduncle is supportive of a diagnosis of Friedreich ataxia because the efferent fibers of the dentate are carried by this tract. However, involvement of these nuclei and tracts is typically not visible with conventional imaging sequences. Diffusion-weighted and diffusion tensor imaging have been used to detect these changes that are not readily apparent.53

Canavan Disease.

Canavan disease, or spongiform leukodystrophy, is an autosomal recessive disorder. The incidence of Canavan disease is estimated to be <1:100,000 in the general population and between 1:6000 and 1:14,000 in the Ashkenazi Jewish population.54,55 A mutation in the ASPA gene causes a deficiency of aspartoacyclase, resulting in a buildup of NAA, which impedes the production of new myelin and causes progressive damage to existing myelin.56,57 At postmortem examination, the white matter of brains with Canavan disease is described as edematous, gelatinous, and vacuolated, and these changes can be seen with imaging.58 Symptoms present within the first 3–6 months of life and prognosis is poor, with most affected children dying before 5 years of age.57 Treatment consists of symptom management and supportive care.

Diffuse cerebral atrophy and extensive white matter changes are characteristic of Canavan disease. The peripheral white matter is affected preferentially in the early stages of the disease.59 As the disease progresses, the globus pallidus is often atrophied, with sparing of the putamen.58,60 MR spectroscopy can be helpful in detecting elevated NAA ratios.59,61 There is variable involvement of the dentate, thalamus, brain stem, and dorsal pons. MR imaging is most helpful for evaluating the extensive white matter involvement characterized by bilaterally symmetric diffuse T2 hyperintensity and diffusion restriction.58,60

Glutaric Aciduria Type 1.

Glutaric aciduria type 1 is a rare autosomal recessive disorder that is estimated to affect 1 in every 100,000 neonates.62 In glutaric aciduria type 1, glutaric acid and 3-hydroxyglutaric acid accumulation causes neuronal hypoplasia. Glutaric aciduria type 1 usually has no signs or symptoms in the first few months of life except for microencephalic macrocephaly.63 Acute decompensation and rapid neurologic deterioration often occur following a febrile illness between 6 and 18 months of age. Symptoms include hypotonia, spasticity, dysphagia, and an increased propensity for bleeding.64 Chronic treatment involves a low lysine diet and carnitine supplementation. Many patients survive to adulthood with marked motor and coordination disability.

Even before the acute decompensation stage, patients with glutaric aciduria type 1 almost invariably have bilateral, cystlike widening of the Sylvian fissures and mesencephalic cistern, with atrophy of the frontotemporal cortices.63,65 During and after an acute decompensation event, T2-weighted hyperintensity on MR imaging and diffusion restriction on DWI are seen in the dentate nucleus, basal ganglia, periventricular white matter, and pontine medial lemniscus.65 These changes represent demyelination and edema following toxic metabolic by-product buildup. Subdural hemorrhage and hygroma can present following minor head trauma because these patients have a propensity for tearing bridging veins and arachnoid membrane fenestrations.66

Maple Syrup Urine Disease.

Maple syrup urine disease is an autosomal recessive disorder that has been estimated to affect 1 in 185,000 neonates worldwide.67 Mutations in the genes that encode for the branched-chain α-keto acid dehydrogenase complex cause a defect in the catabolism of leucine, isoleucine, and valine. If left untreated, buildup of these branched-chain amino acids and their ketoacidotic by-products can lead to rapid neurologic decline, coma, and death. With the adoption of neonate screening for maple syrup urine disease, prognosis is good in the modern world.

Untreated patients with maple syrup urine disease show no abnormalities on CT or MR imaging during their asymptomatic first few days of life.68 The 4 deep cerebellar nuclei, dorsal brain stem, cerebral peduncles, and posterior limb of the internal capsule become severely edematous about 1 week after birth at the onset of symptoms.69 Generalized edema of the brain is often superimposed on these severe, localized changes. DWI will demonstrate markedly restricted diffusion within the affected structures.69 MR spectroscopy can demonstrate abnormal peaks corresponding to increased levels of leucine, isoleucine, and valine. Edema can persist for up to 7 weeks, even if treatment is initiated promptly after the onset of symptoms. If maple syrup urine disease is treated and edema subsides, MR imaging and DWI findings rarely return to normal. Residual abnormalities include diffuse atrophy, dysmyelination, and demarcated lesions in the dentate nuclei, hypothalamus, and cerebral white matter. MR spectroscopy may show decreased, but still abnormally high, peaks corresponding to the branched-chain amino acids.69

Clues from Commonalities and Avenues for Future Research

The dentate nucleus is particularly susceptible to insults, whether demyelination, mineral deposition, or metabolic by-product buildup. The 3 other deep cerebellar nuclei and other deep gray matter structures are, for unclear reasons, often spared in these conditions. It may be that the dentate has innate biologic and metabolic characteristics that allow pathologic processes to preferentially affect it. The neurologic and pathologic effects of dentate involvement in the above-mentioned diseases have not been well-studied. Future studies examining disease-associated histopathologic changes, imaging characteristics, and natural history are needed to better characterize the pathophysiology and consequences of disease involvement of the dentate.

Conclusions

Relatively few inheritable diseases and pathologic processes affect the dentate nucleus. A summary of these diseases, their classic clinical presentations, and their radiographic features are provided in the On-line Table. The symptoms associated with these conditions can be nonspecific and complex, but the use of imaging can aid in narrowing wide differential diagnoses. Because some of these conditions are reversible or medically manageable if the diagnosis is made early enough, it is important to have a diagnostic approach for evaluating imaging features of the dentate (Fig 1).

Footnotes

  • Disclosures: David F. Kallmes—UNRELATED: Grants/Grants Pending: GE Healthcare, Comments: preclinical research support.* *Money paid to the institution.

Indicates open access to non-subscribers at www.ajnr.org

REFERENCES

  1. 1.↵
    1. Rhoton AL Jr.
    . Cerebellum and fourth ventricle. Neurosurgery 2000;47:S7–27 doi:10.1097/00006123-200009001-00007 pmid:10983303
    CrossRefPubMed
  2. 2.↵
    1. Akakin A,
    2. Peris-Celda M,
    3. Kilic T, et al
    . The dentate nucleus and its projection system in the human cerebellum: the dentate nucleus microsurgical anatomical study. Neurosurgery 2014;74:401–24; discussion 424–25 doi:10.1227/NEU.0000000000000293 pmid:24448179
    CrossRefPubMed
  3. 3.↵
    1. O'Halloran CJ,
    2. Kinsella GJ,
    3. Storey E
    . The cerebellum and neuropsychological functioning: a critical review. J Clin Exp Neuropsychol 2012;34:35–56 doi:10.1080/13803395.2011.614599 pmid:22047489
    CrossRefPubMed
  4. 4.↵
    1. Schmahmann JD,
    2. Sherman JC
    . The cerebellar cognitive affective syndrome. Brain 1998;121(pt 4):561–79 doi:10.1093/brain/121.4.561 pmid:9577385
    CrossRefPubMed
  5. 5.↵
    1. Timmann D,
    2. Drepper J,
    3. Frings M, et al
    . The human cerebellum contributes to motor, emotional and cognitive associative learning: a review. Cortex 2010;46:845–57 doi:10.1016/j.cortex.2009.06.009 pmid:19665115
    CrossRefPubMed
  6. 6.↵
    1. Salamon N,
    2. Sicotte N,
    3. Drain A, et al
    . White matter fiber tractography and color mapping of the normal human cerebellum with diffusion tensor imaging. J Neuroradiol 2007;34:115–28 doi:10.1016/j.neurad.2007.03.002 pmid:17481730
    CrossRefPubMed
  7. 7.↵
    1. Suzuki L,
    2. Coulon P,
    3. Sabel-Goedknegt EH, et al
    . Organization of cerebral projections to identified cerebellar zones in the posterior cerebellum of the rat. J Neurosci 2012;32:10854–69 doi:10.1523/JNEUROSCI.0857-12.2012 pmid:22875920
    Abstract/FREE Full Text
  8. 8.↵
    1. Hoover JE,
    2. Strick PL
    . The organization of cerebellar and basal ganglia outputs to primary motor cortex as revealed by retrograde transneuronal transport of herpes simplex virus type I. J Neurosci 1999;19:1446–63 pmid:9952421
    Abstract/FREE Full Text
  9. 9.↵
    1. Guillan G,
    2. Mollaret P
    . Two cases of synchronous and rhythmical velopharyngo-laryngo-oculo-diaphragmatic myoclonus: the anatomical and physiopathological problem of this syndrome. Rev Neurol 1931;2:545–66
  10. 10.↵
    1. Murdoch S,
    2. Shah P,
    3. Jampana R
    . The Guillain-Mollaret triangle in action. Pract Neurol 2016;16:243–46 doi:10.1136/practneurol-2015-001142 pmid:26740379
    Abstract/FREE Full Text
  11. 11.↵
    1. Shaikh AG,
    2. Hong S,
    3. Liao K, et al
    . Oculopalatal tremor explained by a model of inferior olivary hypertrophy and cerebellar plasticity. Brain 2010;133:923–40 doi:10.1093/brain/awp323 pmid:20080879
    CrossRefPubMed
  12. 12.↵
    1. Wakai S,
    2. Nagai M
    . Histological verification of microaneurysms as a cause of cerebral-hemorrhage in surgical specimens. J Neurol Neurosugr Psychiatry 1989;52:595–99 doi:10.1136/jnnp.52.5.595 pmid:2732728
    Abstract/FREE Full Text
  13. 13.↵
    1. Kanno T,
    2. Sano H,
    3. Shinomiya Y, et al
    . Role of surgery in hypertensive intracerebral hematoma: a comparative study of 305 nonsurgical and 154 surgical cases. J Neurosurg 1984;61:1091–99 doi:10.3171/jns.1984.61.6.1091 pmid:6502238
    CrossRefPubMed
  14. 14.↵
    1. Fazekas F,
    2. Kleinert R,
    3. Roob G, et al
    . Histopathologic analysis of foci of signal loss on gradient-echo T2*-weighted MR images in patients with spontaneous intracerebral hemorrhage: evidence of microangiopathy-related microbleeds. AJNR Am J Neuroradiol 1999;20:637–42 pmid:10319975
    Abstract/FREE Full Text
  15. 15.↵
    1. Frytak S,
    2. Moertel CH,
    3. Childs DS
    . Neurologic toxicity associated with high-dose metronidazole therapy. Ann Intern Med 1978;88:361–62 doi:10.7326/0003-4819-88-3-361 pmid:629500
    CrossRefPubMed
  16. 16.↵
    1. Ahmed A,
    2. Loes DJ,
    3. Bressler EL
    . Reversible magnetic resonance imaging findings in metronidazole-induced encephalopathy. Neurology 1995;45:588–89 doi:10.1212/WNL.45.3.588 pmid:7898724
    CrossRefPubMed
  17. 17.↵
    1. Horlen CK,
    2. Seifert CF,
    3. Malouf CS
    . Toxic metronidazole-induced MRI changes. Ann Pharmacother 2000;34:1273–75 doi:10.1345/aph.10028 pmid:11098341
    CrossRefPubMed
  18. 18.↵
    1. Woodruff BK,
    2. Wijdicks EF,
    3. Marshall WF
    . Reversible metronidazole-induced lesions of the cerebellar dentate nuclei. N Engl J Med 2002;346:68–69 doi:10.1056/NEJM200201033460117 pmid:11778010
    CrossRefPubMed
  19. 19.↵
    1. White GW,
    2. Gibby WA,
    3. Tweedle MF
    . Comparison of Gd(DTPA-BMA) (Omniscan) versus Gd(HP-DO3A) (ProHance) relative to gadolinium retention in human bone tissue by inductively coupled plasma mass spectroscopy. Invest Radiol 2006;41:272–78 doi:10.1097/01.rli.0000186569.32408.95 pmid:16481910
    CrossRefPubMed
  20. 20.↵
    1. Kanda T,
    2. Ishii K,
    3. Kawaguchi H, et al
    . High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: relationship with increasing cumulative dose of a gadolinium-based contrast material. Radiology 2014;270:834–41 doi:10.1148/radiol.13131669 pmid:24475844
    CrossRefPubMed
  21. 21.↵
    1. Radbruch A,
    2. Weberling LD,
    3. Kieslich PJ, et al
    . Gadolinium retention in the dentate nucleus and globus pallidus is dependent on the class of contrast agent. Radiology 2015;275:783–91 doi:10.1148/radiol.2015150337 pmid:25848905
    CrossRefPubMed
  22. 22.↵
    1. Stojanov D,
    2. Aracki-Trenkic A,
    3. Benedeto-Stojanov D
    . Gadolinium deposition within the dentate nucleus and globus pallidus after repeated administrations of gadolinium-based contrast agents-current status. Neuroradiology 2016;58:433–41 doi:10.1007/s00234-016-1658-1 pmid:26873830
    CrossRefPubMed
  23. 23.↵
    1. McDonald RJ,
    2. McDonald JS,
    3. Kallmes DF, et al
    . Intracranial gadolinium deposition after contrast-enhanced MR imaging. Radiology 2015;275:772–82 doi:10.1148/radiol.15150025 pmid:25742194
    CrossRefPubMed
  24. 24.↵
    1. Welk B,
    2. McArthur E,
    3. Morrow SA, et al
    . Association between gadolinium contrast exposure and the risk of parkinsonism. JAMA 2016;316:96–98 doi:10.1001/jama.2016.8096 pmid:27380348
    CrossRefPubMed
  25. 25.↵
    1. Noseworthy JH,
    2. Lucchinetti C,
    3. Rodriguez M, et al
    . Multiple sclerosis. N Engl J Med 2000;343:938–52 doi:10.1056/NEJM200009283431307 pmid:11006371
    CrossRefPubMed
  26. 26.↵
    1. Anderson VM,
    2. Fisniku LK,
    3. Altmann DR, et al
    . MRI measures show significant cerebellar gray matter volume loss in multiple sclerosis and are associated with cerebellar dysfunction. Mult Scler 2009;15:811–17 doi:10.1177/1352458508101934 pmid:19465449
    CrossRefPubMed
  27. 27.↵
    1. Fisher E,
    2. Lee JC,
    3. Nakamura K, et al
    . Gray matter atrophy in multiple sclerosis: a longitudinal study. Ann Neurol 2008;64:255–65 doi:10.1002/ana.21436 pmid:18661561
    CrossRefPubMed
  28. 28.↵
    1. Gilmore CP,
    2. Geurts JJ,
    3. Evangelou N, et al
    . Spinal cord grey matter lesions in multiple sclerosis detected by post-mortem high field MR imaging. Mult Scler 2009;15:180–88 pmid:18845658
    CrossRefPubMed
  29. 29.↵
    1. Du SL,
    2. Sah SK,
    3. Zeng C, et al
    . Iron deposition in the gray matter in patients with relapse-remitting multiple sclerosis: a longitudinal study using three-dimensional (3D)-enhanced T2*-weighted angiography (ESWAN). Eur J Radiol 2015;84:1325–32 doi:10.1016/j.ejrad.2015.04.013 pmid:25959392
    CrossRefPubMed
  30. 30.↵
    1. Roccatagliata L,
    2. Vuolo L,
    3. Bonzano L, et al
    . Multiple sclerosis: hyperintense dentate nucleus on unenhanced T1-weighted MR images is associated with the secondary progressive subtype. Radiology 2009;251:503–10 doi:10.1148/radiol.2511081269 pmid:19401576
    CrossRefPubMed
  31. 31.↵
    1. Tjoa CW,
    2. Benedict RH,
    3. Weinstock-Guttman B, et al
    . MRI T2 hypointensity of the dentate nucleus is related to ambulatory impairment in multiple sclerosis. J Neurol Sci 2005;234:17–24 doi:10.1016/j.jns.2005.02.009 pmid:15993137
    CrossRefPubMed
  32. 32.↵
    1. Pawate S,
    2. Wang L,
    3. Song Y, et al
    . Analysis of T2 intensity by magnetic resonance imaging of deep gray matter nuclei in multiple sclerosis patients: effect of immunomodulatory therapies. J Neuroimaging 2012;22:137–44 doi:10.1111/j.1552-6569.2011.00622.x pmid:21707826
    CrossRefPubMed
  33. 33.↵
    1. Stankiewicz JM,
    2. Neema M,
    3. Ceccarelli A
    . Iron and multiple sclerosis. Neurobiol Aging 2014;35(suppl 2):S51–58 doi:10.1016/j.neurobiolaging.2014.03.039 pmid:24929968
    CrossRefPubMed
  34. 34.↵
    1. Hogarth P
    . Neurodegeneration with brain iron accumulation: diagnosis and management. J Mov Disord 2015;8:1–13 doi:10.14802/jmd.14034 pmid:25614780
    CrossRefPubMed
  35. 35.↵
    1. Salomão RP,
    2. Pedroso JL,
    3. Gama MT, et al
    . A diagnostic approach for neurodegeneration with brain iron accumulation: clinical features, genetics and brain imaging. Arq Neuropsiquiatr 2016;74:587–96 doi:10.1590/0004-282X20160080 pmid:27487380
    CrossRefPubMed
  36. 36.↵
    1. Saleem S,
    2. Aslam HM,
    3. Anwar M, et al
    . Fahr's syndrome: literature review of current evidence. Orphanet J Rare Dis 2013;8:156 doi:10.1186/1750-1172-8-156 pmid:24098952
    CrossRefPubMed
  37. 37.↵
    1. Avrahami E,
    2. Cohn DF,
    3. Feibel M, et al
    . MRI demonstration and CT correlation of the brain in patients with idiopathic intracerebral calcification. J Neurol 1994;241:381–84 doi:10.1007/BF02033355 pmid:7931433
    CrossRefPubMed
  38. 38.↵
    1. Elshimali Y
    . The value of differential diagnosis of Fahr's disease by radiology. Internet J Radiol 2004;4. http://ispub.com/IJRA/4/1/9320. Accessed April 3, 2017.
  39. 39.↵
    1. Govindarajan A
    . Imaging in Fahr's disease: how CT and MRI differ? BMJ Case Rep 2013;2013 doi:10.1136/bcr-2013-201523 pmid:24285810
    FREE Full Text
  40. 40.↵
    1. Kobari M,
    2. Nogawa S,
    3. Sugimoto Y, et al
    . Familial idiopathic brain calcification with autosomal dominant inheritance. Neurology 1997;48:645–49 doi:10.1212/WNL.48.3.645 pmid:9065541
    Abstract/FREE Full Text
  41. 41.↵
    1. Castro-Gago M,
    2. Blanco-Barca MO,
    3. Campos-González Y, et al
    . Epidemiology of pediatric mitochondrial respiratory chain disorders in northwest Spain. Pediatr Neurol 2006;34:204–11 doi:10.1016/j.pediatrneurol.2005.07.011 pmid:16504790
    CrossRefPubMed
  42. 42.↵
    1. Zhu ZQ,
    2. Yao JB,
    3. Johns T, et al
    . SURF1, encoding a factor involved in the biogenesis of cytochrome c oxidase, is mutated in Leigh syndrome. Nat Genet 1998;20:337–43 doi:10.1038/3804 pmid:9843204
    CrossRefPubMed
  43. 43.↵
    1. Lee HF,
    2. Tsai CR,
    3. Chi CS, et al
    . Leigh syndrome: clinical and neuroimaging follow-up. Pediatr Neurol 2009;40:88–93 doi:10.1016/j.pediatrneurol.2008.09.020 pmid:19135620
    CrossRefPubMed
  44. 44.↵
    1. Finsterer J
    . Leigh and Leigh-like syndrome in children and adults. Pediatr Neurol 2008;39:223–35 doi:10.1016/j.pediatrneurol.2008.07.013 pmid:18805359
    CrossRefPubMed
  45. 45.↵
    1. Arii J,
    2. Tanabe Y
    . Leigh syndrome: serial MR imaging and clinical follow-up. AJNR Am J Neuroradiol 2000;21:1502–09 pmid:11003287
    Abstract/FREE Full Text
  46. 46.↵
    1. Sonam K,
    2. Khan NA,
    3. Bindu PS, et al
    . Clinical and magnetic resonance imaging findings in patients with Leigh syndrome and SURF1 mutations. Brain Dev 2014;36:807–12 doi:10.1016/j.braindev.2013.10.012 pmid:24262866
    CrossRefPubMed
  47. 47.↵
    1. Pandolfo M
    . Friedreich ataxia: the clinical picture. J Neurol 2009;256(suppl 1):3–8 doi:10.1007/s00415-009-1002-3 pmid:19283344
    CrossRefPubMed
  48. 48.↵
    1. Koeppen AH
    . Friedreich's ataxia: pathology, pathogenesis, and molecular genetics. J Neurol Sci 2011;303:1–12 doi:10.1016/j.jns.2011.01.010 pmid:21315377
    CrossRefPubMed
  49. 49.↵
    1. Mascalchi M,
    2. Salvi F,
    3. Piacentini S, et al
    . Friedreich's ataxia: MR findings involving the cervical portion of the spinal cord. AJR Am J Roentgenol 1994;163:187–91 doi:10.2214/ajr.163.1.8010211 pmid:8010211
    CrossRefPubMed
  50. 50.↵
    1. Koeppen AH,
    2. Michael SC,
    3. Knutson MD, et al
    . The dentate nucleus in Friedreich's ataxia: the role of iron-responsive proteins. Acta Neuropathol 2007;114:163–73 doi:10.1007/s00401-007-0220-y pmid:17443334
    CrossRefPubMed
  51. 51.↵
    1. Koeppen AH,
    2. Ramirez RL,
    3. Yu D, et al
    . Friedreich's ataxia causes redistribution of iron, copper, and zinc in the dentate nucleus. Cerebellum 2012;11:845–60 doi:10.1007/s12311-012-0383-5 pmid:22562713
    CrossRefPubMed
  52. 52.↵
    1. Selvadurai LP,
    2. Harding IH,
    3. Corben LA, et al
    . Cerebral and cerebellar grey matter atrophy in Friedreich ataxia: the IMAGE-FRDA study. J Neurol 2016;263:2215–23 doi:10.1007/s00415-016-8252-7 pmid:27522354
    CrossRefPubMed
  53. 53.↵
    1. Rizzo G,
    2. Tonon C,
    3. Valentino ML, et al
    . Brain diffusion-weighted imaging in Friedreich's ataxia. Mov Disord 2011;26:705–12 doi:10.1002/mds.23518 pmid:21370259
    CrossRefPubMed
  54. 54.↵
    1. Feigenbaum A,
    2. Moore R,
    3. Clarke J, et al
    . Canavan disease: carrier-frequency determination in the Ashkenazi Jewish population and development of a novel molecular diagnostic assay. Am J Med Genet A 2004;124A:142–47 doi:10.1002/ajmg.a.20334 pmid:14699612
    CrossRefPubMed
  55. 55.↵
    1. Kronn D,
    2. Oddoux C,
    3. Phillips J, et al
    . Prevalence of Canavan disease heterozygotes in the New York metropolitan Ashkenazi Jewish population. Am J Hum Genet 1995;57:1250–52 pmid:7485179
    PubMed
  56. 56.↵
    1. Matalon R,
    2. Michals K,
    3. Sebesta D, et al
    . Aspartoacylase deficiency and N-acetylaspartic aciduria in patients with Canavan disease. Am J Med Genet 1988;29:463–71 doi:10.1002/ajmg.1320290234 pmid:3354621
    CrossRefPubMed
  57. 57.↵
    1. Namboodiri AM,
    2. Peethambaran A,
    3. Mathew R, et al
    . Canavan disease and the role of N-acetylaspartate in myelin synthesis. Mol Cell Endocrinol 2006;252:216–23 doi:10.1016/j.mce.2006.03.016 pmid:16647192
    CrossRefPubMed
  58. 58.↵
    1. Brismar J,
    2. Brismar G,
    3. Gascon G, et al
    . Canavan disease: CT and MR imaging of the brain. AJNR Am J Neuroradiol 1990;11:805–10 pmid:2114773
    Abstract/FREE Full Text
  59. 59.↵
    1. Sener RN
    . Canavan disease: diffusion magnetic resonance imaging findings. J Comput Assist Tomogr 2003;27:30–33 doi:10.1097/00004728-200301000-00006 pmid:12544239
    CrossRefPubMed
  60. 60.↵
    1. McAdams HP,
    2. Geyer CA,
    3. Done SL, et al
    . CT and MR imaging of Canavan disease. AJNR Am J Neuroradiol 1990;11:397–99 pmid:2107726
    FREE Full Text
  61. 61.↵
    1. Wittsack HJ,
    2. Kugel H,
    3. Roth B, et al
    . Quantitative measurements with localized 1H MR spectroscopy in children with Canavan's disease. J Magn Reson Imaging 1996;6:889–93 doi:10.1002/jmri.1880060609 pmid:8956134
    CrossRefPubMed
  62. 62.↵
    1. Lindner M,
    2. Kölker S,
    3. Schulze A, et al
    . Neonatal screening for glutaryl-CoA dehydrogenase deficiency. J Inherit Metab Dis 2004;27:851–59 doi:10.1023/B:BOLI.0000045769.96657.af pmid:15505392
    CrossRefPubMed
  63. 63.↵
    1. Mohammad SA,
    2. Abdelkhalek HS,
    3. Ahmed KA, et al
    . Glutaric aciduria type 1: neuroimaging features with clinical correlation. Pediatr Radiol 2015;45:1696–705 doi:10.1007/s00247-015-3395-8 pmid:26111870
    CrossRefPubMed
  64. 64.↵
    1. Wang Q,
    2. Li X,
    3. Ding Y, et al
    . Clinical and mutational spectra of 23 Chinese patients with glutaric aciduria type 1. Brain Dev 2014;36:813–22 doi:10.1016/j.braindev.2013.11.006 pmid:24332224
    CrossRefPubMed
  65. 65.↵
    1. Brismar J,
    2. Ozand PT
    . CT and MR of the brain in glutaric acidemia type I: a review of 59 published cases and a report of 5 new patients. AJNR Am J Neuroradiol 1995;16:675–83 pmid:7611022
    Abstract
  66. 66.↵
    1. Vester ME,
    2. Visser G,
    3. Wijburg FA, et al
    . Occurrence of subdural hematomas in Dutch glutaric aciduria type 1 patients. Eur J Pediatr 2016;175:1001–06 doi:10.1007/s00431-016-2734-6 pmid:27246831
    CrossRefPubMed
  67. 67.↵
    1. Harper PA,
    2. Healy PJ,
    3. Dennis JA
    . Maple Syrup Urine Disease (Branched-Chain Ketoaciduria). New York: McGraw-Hill; 2001:1971–2006
  68. 68.↵
    1. Brismar J,
    2. Aqeel A,
    3. Brismar G, et al
    . Maple syrup urine disease: findings on CT and MR scans of the brain in 10 infants. AJNR Am J Neuroradiol 1990;11:1219–28 pmid:2124065
    Abstract/FREE Full Text
  69. 69.↵
    1. Gupta AK,
    2. Chowdhury V,
    3. Khandelwal N
    . Diagnostic Radiology Paediatric Imaging. New Delhi: Jaypee Brothers Medical Publishers; 2011:522
  • © 2017 by American Journal of Neuroradiology
View Abstract
PreviousNext
Back to top

In this issue

American Journal of Neuroradiology: 38 (8)
American Journal of Neuroradiology
Vol. 38, Issue 8
1 Aug 2017
  • Table of Contents
  • Index by author
  • Complete Issue (PDF)
Advertisement
Print
Download PDF
Email Article

Thank you for your interest in spreading the word on American Journal of Neuroradiology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Dentate Update: Imaging Features of Entities That Affect the Dentate Nucleus
(Your Name) has sent you a message from American Journal of Neuroradiology
(Your Name) thought you would like to see the American Journal of Neuroradiology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Dentate Update: Imaging Features of Entities That Affect the Dentate Nucleus
K.M. Bond, W. Brinjikji, L.J. Eckel, D.F. Kallmes, R.J. McDonald, C.M. Carr
American Journal of Neuroradiology Aug 2017, 38 (8) 1467-1474; DOI: 10.3174/ajnr.A5138

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Dentate Update: Imaging Features of Entities That Affect the Dentate Nucleus
K.M. Bond, W. Brinjikji, L.J. Eckel, D.F. Kallmes, R.J. McDonald, C.M. Carr
American Journal of Neuroradiology Aug 2017, 38 (8) 1467-1474; DOI: 10.3174/ajnr.A5138
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Purchase

Jump to section

  • Article
    • Abstract
    • ABBREVIATION:
    • Conclusions
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • References
  • PDF

Related Articles

  • PubMed
  • Google Scholar

Cited By...

  • Gadolinium Retention in the Brain: An MRI Relaxometry Study of Linear and Macrocyclic Gadolinium-Based Contrast Agents in Multiple Sclerosis
  • Novel genotype-phenotype and MRI correlations in a large cohort of patients with SPG7 mutations
  • Reversible cerebellar neurotoxicity induced by metronidazole
  • Crossref
  • Google Scholar

This article has not yet been cited by articles in journals that are participating in Crossref Cited-by Linking.

More in this TOC Section

  • Clinical Profiles and Patterns of Neurodegeneration in Amyotrophic Lateral Sclerosis: A Cluster-Based Approach Based on MR Imaging Metrics
  • Comparison between Dual-Energy CT and Quantitative Susceptibility Mapping in Assessing Brain Iron Deposition in Parkinson Disease
  • Incidental Findings from 16,400 Brain MRI Examinations of Research Volunteers
Show more Adult Brain

Similar Articles

Advertisement

News and Updates

  • Lucien Levy Best Research Article Award
  • Thanks to our 2022 Distinguished Reviewers
  • Press Releases

Resources

  • Evidence-Based Medicine Level Guide
  • How to Participate in a Tweet Chat
  • AJNR Podcast Archive
  • Ideas for Publicizing Your Research
  • Librarian Resources
  • Terms and Conditions

Opportunities

  • Share Your Art in Perspectives
  • Get Peer Review Credit from Publons
  • Moderate a Tweet Chat

American Society of Neuroradiology

  • Neurographics
  • ASNR Annual Meeting
  • Fellowship Portal
  • Position Statements

© 2023 by the American Society of Neuroradiology | Print ISSN: 0195-6108 Online ISSN: 1936-959X

Powered by HighWire